ES2167356T3 - Utilizacion de tioureilenos y tiabendazol en enfermedades autoinmunitarias e inflamatorias de la piel. - Google Patents
Utilizacion de tioureilenos y tiabendazol en enfermedades autoinmunitarias e inflamatorias de la piel.Info
- Publication number
- ES2167356T3 ES2167356T3 ES94902447T ES94902447T ES2167356T3 ES 2167356 T3 ES2167356 T3 ES 2167356T3 ES 94902447 T ES94902447 T ES 94902447T ES 94902447 T ES94902447 T ES 94902447T ES 2167356 T3 ES2167356 T3 ES 2167356T3
- Authority
- ES
- Spain
- Prior art keywords
- thiourethylens
- thiabendazol
- autoimmunity
- skin diseases
- inflammatory skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
LA INVENCION PROPORCIONA NUEVOS USOS DE FARMACOS DE LA CLASE DEL TIOUREILENO Y TIABENDAZOLES. ESTOS NUEVOS USOS INCLUYEN METODOS DE TRATAMIENTO PARA UNA VARIEDAD DE CONDICIONES Y ENFERMEDADES, INCLUYENDO LA SORIASIS, OTRAS DERMATOSIS ATOPICAS Y CONDICIONES INFLAMATORIAS QUE TIENEN UNA BASE AUTOINMUNE, ASI COMO OTRAS ENFERMEDADES AUTOINMUNES, INCLUYENDO ENFERMEDADES REUMATICAS, Y RECHAZO DE TRANSPLANTE.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/982,702 US5310742A (en) | 1992-11-30 | 1992-11-30 | Uses for thioureylenes |
PCT/US1993/011537 WO1994012183A1 (en) | 1992-11-30 | 1993-11-30 | Use of thioureleylenes and thiabendazole in autoimmune diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2167356T3 true ES2167356T3 (es) | 2002-05-16 |
Family
ID=25529427
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES94902447T Expired - Lifetime ES2167356T3 (es) | 1992-11-30 | 1993-11-30 | Utilizacion de tioureilenos y tiabendazol en enfermedades autoinmunitarias e inflamatorias de la piel. |
Country Status (6)
Country | Link |
---|---|
US (1) | US5310742A (es) |
EP (1) | EP0670723B1 (es) |
AU (1) | AU5681694A (es) |
DE (1) | DE69331105T2 (es) |
ES (1) | ES2167356T3 (es) |
WO (1) | WO1994012183A1 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2164641A1 (en) * | 1993-06-07 | 1994-12-22 | Dinah S. Singer | Use of an mhc class i suppressor drug for the treatment of autoimmune diseases and transplantation rejection |
US6365616B1 (en) | 1998-08-31 | 2002-04-02 | Sentron Medical, Inc. | Methimazole derivatives and tautomeric cyclic thiones to treat autoimmune diseases |
US20020142974A1 (en) * | 1998-09-11 | 2002-10-03 | Leonard D. Kohn | Immune activation by double-stranded polynucleotides |
US7288516B1 (en) | 1999-09-20 | 2007-10-30 | Celtrix Pharmaceuticals, Inc. | Null IGF for the treatment of cancer |
CA2345642A1 (en) * | 1998-10-02 | 2000-04-13 | Celtrix Pharmaceuticals, Inc. | Methods for the treatment of non-thyroid disorders |
ATE303159T1 (de) * | 1998-10-02 | 2005-09-15 | Celtrix Pharma | Null igf zur krebsbehandlung |
US20050003023A1 (en) * | 2002-06-28 | 2005-01-06 | Meisner Lorraine Faxon | Topical composition for the treatment of psoriasis and related skin disorders |
US6440465B1 (en) * | 2000-05-01 | 2002-08-27 | Bioderm, Inc. | Topical composition for the treatment of psoriasis and related skin disorders |
US6939863B2 (en) | 2002-01-04 | 2005-09-06 | Wei-Jan Chen | Prevention of atherosclerosis and restenosis |
AU2003299560A1 (en) * | 2002-11-13 | 2004-06-03 | Sepracor, Inc. | Compositions and methods for treating or preventing hearing impairment |
AU2005282789A1 (en) * | 2004-09-01 | 2006-03-16 | Trustees Of Boston University | Use of thyroid hormone conversion inhibitors |
EP2251010A1 (en) | 2009-05-08 | 2010-11-17 | Sygnis Bioscience GmbH & Co. KG | Use of thiabendazole and derivatives thereof for the therapy of neurological conditions |
GB2527555B (en) | 2014-06-25 | 2018-09-19 | Norbrook Lab Ltd | Stable methimazole liquid compositions |
US10238664B2 (en) | 2014-07-09 | 2019-03-26 | Duke University | Compositions and methods for the repair of myelin |
CA3050001A1 (en) * | 2017-01-13 | 2018-07-19 | Duke University | Compositions and methods for the treatment of myelin related and inflammation related diseases or disorders |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4457907A (en) * | 1982-08-05 | 1984-07-03 | Clear Lake Development Group | Composition and method for protecting a therapeutic drug |
US4608341A (en) * | 1983-05-31 | 1986-08-26 | Interthyr Research Foundation, Inc. | Living, fast-growing thyroid cell strain, FRTL-5 |
US4609622A (en) * | 1983-05-31 | 1986-09-02 | Interthyr Research Foundation Inc. | Clinical determination and/or quantification of thyrotropin and a variety of thyroid stimulatory or inhibitory factors performed in vitro with an improved thyroid cell line, FRTL-5 |
JPS60100516A (ja) * | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
DE3678308D1 (de) * | 1985-02-07 | 1991-05-02 | Takeda Chemical Industries Ltd | Verfahren zur herstellung von mikrokapseln. |
US4853227A (en) * | 1987-10-23 | 1989-08-01 | Ciba-Geigy Corporation | Transdermal administration of a systemic active agent to a premature neonatal infant |
JP2670680B2 (ja) * | 1988-02-24 | 1997-10-29 | 株式会社ビーエムジー | 生理活性物質含有ポリ乳酸系微小球およびその製造法 |
US5087441A (en) * | 1989-12-22 | 1992-02-11 | Wisconsin Alumni Research Foundation | Protection against chemically-induced kidney damage by methimazole |
US5010092A (en) * | 1989-12-22 | 1991-04-23 | Wisconsin Alumni Research Foundation | Protection against chemically-induced kidney damage by methimazole |
-
1992
- 1992-11-30 US US07/982,702 patent/US5310742A/en not_active Expired - Lifetime
-
1993
- 1993-11-30 DE DE69331105T patent/DE69331105T2/de not_active Expired - Fee Related
- 1993-11-30 AU AU56816/94A patent/AU5681694A/en not_active Abandoned
- 1993-11-30 EP EP94902447A patent/EP0670723B1/en not_active Expired - Lifetime
- 1993-11-30 WO PCT/US1993/011537 patent/WO1994012183A1/en active IP Right Grant
- 1993-11-30 ES ES94902447T patent/ES2167356T3/es not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE69331105T2 (de) | 2002-07-11 |
DE69331105D1 (de) | 2001-12-13 |
EP0670723A1 (en) | 1995-09-13 |
EP0670723B1 (en) | 2001-11-07 |
AU5681694A (en) | 1994-06-22 |
US5310742A (en) | 1994-05-10 |
WO1994012183A1 (en) | 1994-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2167356T3 (es) | Utilizacion de tioureilenos y tiabendazol en enfermedades autoinmunitarias e inflamatorias de la piel. | |
GT199800021A (es) | Utilizacion de antagonistas de los receptores de canabinoides centrales para la preparacion de medicamentos. | |
ES2077530B1 (es) | Procedimiento para la preparacion de productos farmaceuticos para curar enfermedades tumorales. | |
ES2157601T3 (es) | Uso de agentes anti-microtubulos para tratar o prevenir la esclerosis multiple. | |
SV2002000289A (es) | Antagonistas del factor liberador de la corticotropina ref. pc10759/20117/bb | |
NO307968B1 (no) | Pyrazolo- og pyrrolopyridiner og farmasøytisk blanding derav | |
ES2191152T3 (es) | Terapia combinada para el tratamiento de psicosis. | |
ES2171768T3 (es) | Inhibidores de la resorcion osea y antagonistas de receptores de vitronectina. | |
AR026610A1 (es) | Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central | |
ES2171971T3 (es) | Producto limpiador y de tratamiento con almidon. | |
ES2156150T3 (es) | Combinacion terapeutica que contiene interferon. | |
AR030236A1 (es) | Moléculas similares a il-17 y usos de las mismas | |
ES2170771T3 (es) | Atenuacion de un epitopo inmunodominante de un antigeno para su utilizacion en vacunas e inmunoterapias para vegetales, animales y humanos. | |
ES2176354T3 (es) | Uso de nebivolol como agente anti-aterogenico. | |
GT199700115A (es) | Agentes nicotinicos en terapia. | |
ES2060310T3 (es) | Utilizacion de la n-miristoil-(s)-fenilalanina para la obtencion de medicamentos destinados al tratamiento de enfermedades que hacen intervenir la miristoilacion. | |
AR034213A1 (es) | Composiciones de medicamentos sobre la base de agentes anticolinergicos e inhibidores de pde-iv | |
ES2176322T3 (es) | Nuevos peptidos opioides para el tratamiento de dolores y su utilizacion. | |
ES2177636T3 (es) | Utilizacion del agua empobrecida en deuterio en la preparacion de cosmeticos. | |
AR025883A1 (es) | Utilizacion de antagonistas de los receptores de los cannabinoides centrales para la preparacion de medicamentos | |
ATE259237T1 (de) | Verwendung von isoosmotischen salzlösungen zur verhütung von entzündungen | |
ES2093582T1 (es) | Composicion y procedimiento para el moldeado permanente del cabello. | |
ES2170798T3 (es) | Benzopiranos y su uso como agentes terapeuticos. | |
ES2174337T3 (es) | Uso topico de los agonistas opioides kappa para el tratamiento del dolor ocular. | |
AR028772A1 (es) | 5-aminoalquil-pirazol[4,3-d] pirimidinas |